Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Andersson

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Genomics|May 12, 2005
Origin of the prolactin-releasing hormone (PRLH) receptors: evidence of coevolution between PRLH and a redundant neuropeptide Y receptor during vertebrate evolutionMalin C Lagerström, Robert Fredriksson, Thóra K Bjarnadóttir, et al.
European Journal of Immunology|October 31, 2009
A novel human CD4+ T-cell inducer subset with potent immunostimulatory propertiesLishomwa C Ndhlovu, Fabio E Leal, Ijeoma G Eccles-James, et al.
Plos One|November 22, 2008
rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vectorIsabelle Magalhaes, Donata R Sizemore, Raija K Ahmed, et al.
Neuroimage|April 25, 2008
[11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brainM Edward Pierson, Jan Andersson, Svante Nyberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2025
MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screensJan Andersson, Sanne Cowland, Mikkel Vestergaard, et al.
Vaccine|February 21, 2017
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trialsMaria Norrby, Timo Vesikari, Lars Lindqvist, et al.
The Journal of Infectious Diseases|July 20, 2005
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infectionSabine Kinloch-de Loes, Bruno Hoen, Don E Smith, et al.
Nuclear Medicine and Biology|July 11, 2020
Training the next generation of radiopharmaceutical scientistsAntony D Gee, Jan Andersson, Rajiv Bhalla, et al.
Journal of Medicinal Chemistry|March 18, 2025
From DNA-Encoded Library Screening to <b>AM-9747</b>: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo EfficacyIan Sarvary, Mikkel Vestergaard, Loris Moretti, et al.
Cancer Discovery|September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted CancersBrian Belmontes, Katherine K Slemmons, Chun Su, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Genomics|May 12, 2005
Origin of the prolactin-releasing hormone (PRLH) receptors: evidence of coevolution between PRLH and a redundant neuropeptide Y receptor during vertebrate evolutionMalin C Lagerström, Robert Fredriksson, Thóra K Bjarnadóttir, et al.
European Journal of Immunology|October 31, 2009
A novel human CD4+ T-cell inducer subset with potent immunostimulatory propertiesLishomwa C Ndhlovu, Fabio E Leal, Ijeoma G Eccles-James, et al.
Plos One|November 22, 2008
rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vectorIsabelle Magalhaes, Donata R Sizemore, Raija K Ahmed, et al.
Neuroimage|April 25, 2008
[11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brainM Edward Pierson, Jan Andersson, Svante Nyberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2025
MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screensJan Andersson, Sanne Cowland, Mikkel Vestergaard, et al.
Vaccine|February 21, 2017
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trialsMaria Norrby, Timo Vesikari, Lars Lindqvist, et al.
The Journal of Infectious Diseases|July 20, 2005
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infectionSabine Kinloch-de Loes, Bruno Hoen, Don E Smith, et al.
Nuclear Medicine and Biology|July 11, 2020
Training the next generation of radiopharmaceutical scientistsAntony D Gee, Jan Andersson, Rajiv Bhalla, et al.
Journal of Medicinal Chemistry|March 18, 2025
From DNA-Encoded Library Screening to <b>AM-9747</b>: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo EfficacyIan Sarvary, Mikkel Vestergaard, Loris Moretti, et al.
Cancer Discovery|September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted CancersBrian Belmontes, Katherine K Slemmons, Chun Su, et al.
Pageof 16